The patent cliff for Keytruda is fast approaching in the U.S. Now, as Merck & Co. increasingly looks to life after its ...
Sales of Merck’s longtime oncology blockbuster Keytruda will erode more starkly in about 2033 rather than 2029, predicts ...
Merck (NYSE:MRK) reported positive Phase 3 SMART trial results for ENFLONSIA, showing protection against RSV in high risk ...
The winners will not be those who merely predict cliffs, but those who re-architect early enough. Merck’s oncology spin-out underscores a defining reality of modern pharma: molecules may create value, ...
But now, 13 years after the FDA initially blessed it for skin cancer, the U.S. regulator has approved Keytruda as a second- or third-line treatment for patients with a certain type of ovarian cancer.
The new structure will help Merck as it slides toward a loss of exclusivity for Keytruda, pharma’s best-selling drug.
New KEYTRUDA indications are expected to preserve Merck's top line. Click here to read why MRK stock remains a great buy upon ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results